Health & Biotech
Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.
Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Social media platforms scramble to update advertising policies on cannabis products
Health & Biotech
Melodial Global Health delivers record revenue quarter with 105pc uptick in group sales
Health & Biotech
Melodiol’s Canadian subsidiary Mernova reports 42pc lift in Q2 FY23 revenues and record half yearly results
Health & Biotech
Melodiol’s Health House International delivers strong financial result to validate growth strategy
Health & Biotech
Creso Pharma to source high-quality Swiss psychedelics products for Australian market
Health & Biotech
Creso Pharma subsidiary Mernova Medicinal appoints consultant to expedite cannabis exports to Australia and Europe
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
News
CLOSING BELL: A crazy ride for tech stocks and Wildcat as the ASX dips 0.22%
Health & Biotech
Weed Week: Cannabis helps chronic pain and insomnia, and here’s what the TGA rules say
News
CLOSING BELL: Hump Day is Slump Day yet again, as the ASX drops another 0.46%
Health & Biotech
Creso Pharma advances its footprint across Asia Pacific with its line of animal care products
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Welcome to the ASX, where our motto is ‘chin up, mate… it could’ve been worse’
News
ASX Small Caps Lunch Wrap: Who else is trying to dance on the ceiling this morning?
Health & Biotech
Creso’s Groupon deal and mushroom launch pumps potential US market size
News
Rise and Shine: Everything you need to know before the ASX opens
News